Primary localized conjunctival amyloidosis – eyewiki endometrial biopsy procedure

Amyloidosis is caused by the extracellular tissue deposition of amyloid fibrillar proteins. Amyloid fibrils are insoluble polymers comprised of low molecular weight subunit proteins, which adopt a beta-pleated sheet configuration. The deposition of these insoluble proteins can lead to tissue toxicity and disease. At least 27 different human protein precursors of amyloid fibrils are now known. The most frequent types are the AL and AA subtypes. Some types of amyloidosis are hereditary and have been linked to genetic mutations. For others there is no hereditary component.

The most common presenting symptoms include pain and ptosis. However, some patients may remain asymptomatic and the lesion is discovered only incidentally. For patients with periocular or orbital amyloidosis proptosis, globe displacement, diplopia, and limited ocular motility may be observed.


Conjunctival amyloidosis usually appears as confluent fusiform lesions or polypoidal papules that have a salmon-colored or yellow-pink color. Any conjunctival surface may be involved, but the superior fornix and tarsal conjunctiva are the most frequently affected. This deposition may result in ptosis. Patients may also present with recurrent subconjunctival hemorrhage from the accumulation of amyloid in the walls of the blood vessels. The eyelid, extraocular muscles, and lacrimal gland may also be affected by amyloidosis.

Systemic amyloidosis most commonly involves the kidney, the heart, and the liver. Renal involvement may present as asymptomatic proteinuria or nephritic syndrome. End-stage renal disease may result in cases of severe disease. Cardiac involvement may lead to heart failure, arrhythmia, heart block, or even myocardial infarction from amyloid deposition in the coronary arteries. Hepatomegaly with or without splenomegaly may result from amyloid deposition in the liver. Amyloidosis may also result in neurologic, musculoskeletal, hematologic, pulmonary and cutaneous disease.

On hematoxylin-eosin staining, conjunctival amyloid demonstrates homogeneous, amorphous eosinophilic material in the conjunctival stroma. With Congo red staining, there is pathognomonic apple-green birefringence, which demonstrates dichroism with polarization microscopy.

Systemic involvement should be ruled out in any patient who presents with an isolated conjunctival lesion. Amyloidosis can frequently affect the kidney, heart, and liver. Tests for cardiac, liver and kidney function including an echocardiogram and electrocardiogram as well as serum and urine protein electrophoresis should be obtained. More specific immunofixation and free light chain electrophoresis of both the serum and urine should be obtained as well. Other tests such as bone marrow biopsy, abdominal fat biopsy, and rectal biopsy should be considered. Imaging tests such as CT or MRI may be helpful in localizing and detecting the extent of orbital disease.

The clinical differential diagnosis of conjunctival amyloidosis includes lymphoma, leukemia, squamous cell carcinoma, sebaceous cell carcinoma, sarcoidosis, and melanoma. The smooth salmon colored appearance of amyloidosis is similar to lymphoma.

Management modalities include observation, judicious use of artificial tears, excision, or liquid nitrogen cryotherapy for localized conjunctival amyloidosis. For patients with systemic manifestations, stem cell transplant, chemotherapy, and steroids may be considered depending on the extent of the disease. Surgical debulking remains the standard treatment, but because complete excision is not always possible, the disease may recur. Demirci and Leibovitch report a recurrence rate of 21-27% after surgical debulking of localized orbital amyloidosis. Newer therapies such as cryotherapy may further decrease recurrence rate by decreasing blood supply to the surrounding tissue, but more research is needed. Radiotherapy for localized amyloidosis has also been reported but is not considered the standard of care.

For patients with systemic amyloidosis, treatment varies depending on the disease manifestations. Some patients may be considered for chemotherapy and steroids while others may qualify for stem cell transplant. There are multiple clinical trials studying the effect of different chemotherapy agents in treating systemic amyloidosis. Patients with end-stage renal disease may require dialysis or renal transplantation. For patients with hereditary amyloidosis in which abnormal proteins are produced by the liver, liver transplant may lead to regression of the disease.